Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 396

1.
2.

Identification of a glutathione-S-transferase effector domain for inhibition of jun kinase, by molecular dynamics.

Monaco R, Friedman FK, Hyde MJ, Chen JM, Manolatus S, Adler V, Ronai Z, Koslosky W, Pincus MR.

J Protein Chem. 1999 Nov;18(8):859-66.

PMID:
10839622
3.

Glutathione-S-Transferase as a selective inhibitor of oncogenic ras-p21-induced mitogenic signaling through blockade of activation of jun by jun-N-terminal kinase.

Villafania A, Anwar K, Amar S, Chie L, Way D, Chung DL, Adler V, Ronai Z, Brandt-Rauf PW, Yamaizumii Z, Kung HF, Pincus MR.

Ann Clin Lab Sci. 2000 Jan;30(1):57-64.

PMID:
10678584
4.

An effector peptide from glutathione-S-transferase-pi strongly and selectively blocks mitotic signaling by oncogenic ras-p21.

Chie L, Adler V, Friedman FK, Chung D, Pincus MR.

Protein J. 2004 Apr;23(3):235-8.

PMID:
15200055
5.

Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus.

Wang T, Arifoglu P, Ronai Z, Tew KD.

J Biol Chem. 2001 Jun 15;276(24):20999-1003. Epub 2001 Mar 9.

7.

Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK pathways in CD4 T cells.

Mischiati C, Pironi F, Milani D, Giacca M, Mirandola P, Capitani S, Zauli G.

AIDS. 1999 Sep 10;13(13):1637-45.

PMID:
10509564
8.

Induction of oocyte maturation by jun-N-terminal kinase (JNK) on the oncogenic ras-p21 pathway is dependent on the raf-MEK signal transduction pathway.

Chie L, Amar S, Kung HF, Lin MC, Chen H, Chung DL, Adler V, Ronai Z, Friedman FK, Robinson RC, Kovac C, Brandt-Rauf PW, Yamaizumi Z, Michl J, Pincus MR.

Cancer Chemother Pharmacol. 2000;45(6):441-9.

PMID:
10854130
9.

c-Jun N-terminal kinase binding domain-dependent phosphorylation of mitogen-activated protein kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing cross-talk between c-Jun N-terminal kinase and extracellular signal-regulated kinase pathways in cortical neurons.

Repici M, Mare L, Colombo A, Ploia C, Sclip A, Bonny C, Nicod P, Salmona M, Borsello T.

Neuroscience. 2009 Mar 3;159(1):94-103. doi: 10.1016/j.neuroscience.2008.11.049. Epub 2008 Dec 14.

PMID:
19135136
10.

Regulation of JNK signaling by GSTp.

Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ, Ronai Z.

EMBO J. 1999 Mar 1;18(5):1321-34.

11.

COP9 signalosome-directed c-Jun activation/stabilization is independent of JNK.

Naumann M, Bech-Otschir D, Huang X, Ferrell K, Dubiel W.

J Biol Chem. 1999 Dec 10;274(50):35297-300.

12.

c-Jun N-terminal kinase (JNK) positively regulates NFATc2 transactivation through phosphorylation within the N-terminal regulatory domain.

Ortega-Pérez I, Cano E, Were F, Villar M, Vázquez J, Redondo JM.

J Biol Chem. 2005 May 27;280(21):20867-78. Epub 2005 Mar 2.

13.

Disruption of the c-JUN-JNK complex by a cell-permeable peptide containing the c-JUN delta domain induces apoptosis and affects a distinct set of interleukin-1-induced inflammatory genes.

Holzberg D, Knight CG, Dittrich-Breiholz O, Schneider H, Dörrie A, Hoffmann E, Resch K, Kracht M.

J Biol Chem. 2003 Oct 10;278(41):40213-23. Epub 2003 Jun 27.

14.

Complexes of p21RAS with JUN N-terminal kinase and JUN proteins.

Adler V, Pincus MR, Brandt-Rauf PW, Ronai Z.

Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10585-9.

15.

Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide.

Ngoei KR, Catimel B, Church N, Lio DS, Dogovski C, Perugini MA, Watt PM, Cheng HC, Ng DC, Bogoyevitch MA.

Biochem J. 2011 Mar 15;434(3):399-413. doi: 10.1042/BJ20101244.

PMID:
21162712
16.

Differences in patterns of activation of MAP kinases induced by oncogenic ras-p21 and insulin in oocytes.

Ranginwale M, Smith S, Flom J, Chie L, Kanovsky M, Chung D, Friedman FK, Robinson RC, Brandt-Rauf PW, Yamaizumi Z, Michl J, Pincus MR.

Exp Cell Res. 2001 Sep 10;269(1):162-9.

PMID:
11525649
17.

Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun.

Kielosto M, Nummela P, Katainen R, Leaner V, Birrer MJ, Hölttä E.

Cancer Res. 2004 Jun 1;64(11):3772-9.

18.

c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK).

Sevilla A, Santos CR, Barcia R, Vega FM, Lazo PA.

Oncogene. 2004 Nov 25;23(55):8950-8.

PMID:
15378002
19.

Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.

Adler V, Qu Y, Smith SJ, Izotova L, Pestka S, Kung HF, Lin M, Friedman FK, Chie L, Chung D, Boutjdir M, Pincus MR.

Biochemistry. 2005 Aug 16;44(32):10784-95.

PMID:
16086581
20.

Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells.

Adler V, Bowne W, Kamran I, Michl J, Friedman FK, Chin E, Zenilman M, Pincus MR.

Cancer Chemother Pharmacol. 2008 Aug;62(3):491-8. Epub 2007 Dec 8.

PMID:
18066549
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk